In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.
From a multi-billion-pound boost to R&D and life sciences manufacturing, to scaling innovative businesses through the British Business Bank, the Review signals significant investment.
We are heading to Boston this June for the BIO International Convention 2025 – one of the world’s largest and most influential gatherings in the life sciences calendar.
UK biotech financing in Q1 2025 saw a sharp rise in overall equity financing, reaching £924 million across venture capital and follow-on funding. This represents a modest decline compared to £987 million in Q1 2024 but masks a shift in where capital is flowing.
This report is the first step in understanding the specific challenges faced by female CEOs and C-suite in biotechnology in the UK – in order to understand best how we can help to enact change and provide relevant support.
In this guest blog, Christine Hockley, Managing Director at British Patient Capital, outlines the substantial long-term investment needed to scale innovations.
BIA, MedCity, and London & Partners announce the launch of London Life Sciences Week (LLSW), celebrating the UK’s thriving life sciences ecosystem and bringing together international investors, industry leaders, and cutting-edge innovators.
The UK biotech sector demonstrated encouraging resilience in the third quarter of 2024 raising a total of £808 million in venture capital and public financing. Read our latest report to find out more.
The UK biotech sector secured an impressive £808 million in Q3 2024, defying tough global market conditions and demonstrating sustained investor confidence. Read our latest report to find out more.
CGT Catapult has revealed new data highlighting the UK’s potential to become a global leader in the sector. Its 2024 annual review demonstrates how, with coherent and concerted action, the UK can take the lead in harnessing the potential of these therapies to deliver life-changing benefits to patients and economic growth to the nation.
